The IBD outpatient care in the clinical practice

Česká verzia

Authors: Luděk Hrdlička
Authors place of work: Gastroenterologické oddělení Polikliniky Budějovická, Medicon a. s., Praha
Published in the journal: Vnitř Lék 2018; 64(6): 654-658
Category: Original Contributions

Summary

The number of patients with inflammatory bowel disease (Crohn´s disease and ulcerative colitis) has increased steadily. Gastroenterology outpatient secondary type centres play very important role in the care for these patients. Their clinical practice was assessed in our study. The data was obtained using a structured questionnaire concerned on 4 major topics (the centre characteristics, diagnosis, therapy and patient´s monitoring). Obtained data was compared with both local and international recommendations and showed high professional standards of care.

Key words:

Crohn´s disease – diagnosis – inflammatory bowel disease – outpatient care – patient´s monitoring – therapy – ulcerative colitis

Zdroje

Lukáš M. Možnosti medikamentózní léčby Crohnovy choroby a ulcerózní kolitidy. Interní Med 2011; 13(11): 422–426.
Hrdlička L. Péče o IBD pacienty: klinická praxe v gastroenterologických ambulancích sekundárního typu v ČR. Gastroent Hepatol 2014; 68(5): 456–460.
Modigliani R, Mary JY, Simon JF et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98(4): 811–818.
Landi B, Anh TN, Cortot A et al. Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992; 102(5): 1647–1653.
Carbonnel F, Lavergne A, Lemann M et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994; 39(7): 1550–1557.
Horsthuis K, Bipat S, Bennink RJ et al. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: metaanalysis of prospective studies. Radiology 2008; 247(1): 64–79. Dostupné z DOI: <http://dx.doi.org/10.1148/radiol.2471070611>.
Parisinos CA, Mclntyre VE, Heron T et al. Magnetic resonance follow-through imaging for evaluation of disease activity in ileal Crohn’s disease: an observational, retrospective cohort study. Inflamm Bowel Dis 2010; 16(7): 1219–1226. Dostupné z DOI: <http://dx.doi.org/10.1002/ibd.21168>.
Horjus C et al. Magnetic resonance enterography in the assessment of the disease activity in Crohn’s disease. A retrospective study ECCO Congress, Prague 2010; P047.
Girlich C, Ott C, Strauch U et al. Clinical feature and bowel ultrasound in Crohn’s disease – does additional information from magnetic resonance imaging affect therapeutic approach and when does extended diagnostic investigation make sense? Digestion 2011; 83(1–2): 18–23. Dostupné z DOI: <http://dx.doi.org/10.1159/000314590>.
Marino M, Berretti D, Toso F et al. Usefullness of ultrasound in small bowel Crohn’s disease: comparison with magnetic resonance for extension, complications and disease activity. Gut 2011; 60(Suppl 1): A210.2. Dostupné z DOI: <http://dx.doi.org/10.1136/gut.2011.239301.443>.
Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55(3): 426–431. Dostupné z DOI: <http://dx.doi.org/10.1136/gut.2005.069476>.
Keshet R, Boursi B, Maoz R et al. Diagnostic and prognostic significance of serum C-reactive protein levels in patients admitted to the department of medicine. Am J Med Sci 2009; 337(4): 248–255. Dostupné z DOI: <http://dx.doi.org/10.1097/MAJ.0b013e31818af6de>.
Vieira A, Fang CB, Rolim EG et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes 2009; 2: 221. Dostupné z DOI: <http://dx.doi.org/10.1186/1756–0500–2–221>.
Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004; 39(10): 1017–1020. Dostupné z DOI: <http://dx.doi.org/10.1080/00365520410007971>.
Dignass A, Lindsay JO, Sturm A et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6(10): 991–1030. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crohns.2012.09.002>.
Regueiro M, Kip KE, Schraut W et al. Crohn’s disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis 2011; 17(1): 118–126. Dostupné z DOI: <http://dx.doi.org/10.1002/ibd.21355>.
Dignass A, Van Assche G, Lindsay JO et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohn’s Colitis 2010; 4(1): 28–62. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crohns.2009.12.002>. Erratum in J Crohns Colitis 2010; 4(3): 353.
Prokopová L, Ďuricová D, Bortlík M et al. Doporučené postupy pro podávání aminosalicylátů u nemocných s idiopatickými střevními záněty. Gastroent Hepatol 2012; 66(5): 391–400.
Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s Disease. Cochrane Database Syst Rev 2005; (1): CD003715. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD003715.pub2>.
Ford AC, Kane SV, Khan KJ et al. Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106(4): 617–629. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2011.71>.
Ford AC, Khan KJ, Talley NJ et al. 5-aminosalicylates prevent relapse of Crohn’s disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol 2011; 106(3): 413–420. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2010.317>.
Gordon M, Naidoo K, Thomas AG et al. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev 2011; (1): CD008414. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD008414.pub2>.
Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev 2010; (12): CD008870. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD008870>.
Steinhart AH, Forbes A, Mills EC et al. Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn’s disease. Aliment Pharmacol Ther 2007; 25(12): 1389–1399. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2036.2007.03324.x>.
Ďuricová D. Mesalazin u Crohnovy nemoci: obsoletní nebo neprávem opomíjená léčba? Gastroent Hepatol 2013; 67(1): 22–24.
Ananthakrishnan AN, McGinley EL, Binion DG. Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. Am J Gastroenterol 2008; 103(11): 2789–2798. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1572–0241.2008.02054.x>.
Nguyen GC, Steinhart AH. Nationwide patterns of hospitalizations to centers with high volume of admissions for inflammatory bowel disease and their impact on mortality. Inflamm Bowel Dis 2008; 14(12): 1688–1694. Dostupné z DOI: <http://dx.doi.org/10.1002/ibd.20526>.
Burns EM, Bottle A, Aylin P et al. Volume analysis of outcome following restorative proctocolectomy. Br J Surg 2011; 98(3): 408–417. Dostupné z DOI: <http://dx.doi.org/10.1002/bjs.7312>.
Kennedy ED, Rothwell DM, Cohen Z et al. Increased experience and surgical technique lead to improved outcome after ileal pouch-anal anastomosis: a population-based study. Dis Colon Rectum 2006; 49(7): 958–965. Dostupné z DOI: <http://dx.doi.org/10.1007/s10350–006–0521–6>.